WHWK
NASDAQ · Biotechnology
Whitehawk Therapeutics Inc
$3.21
-0.03 (-0.93%)
Financial Highlights (FY 2026)
Revenue
8.05M
Net Income
-23,204,136
Gross Margin
89.4%
Profit Margin
-288.3%
Rev Growth
-22.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.4% | 89.4% | 49.8% | 49.8% |
| Operating Margin | -379.8% | -341.8% | 27.0% | 26.3% |
| Profit Margin | -288.3% | -273.9% | 27.1% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.05M | 10.36M | 8.91M | 7.24M |
| Gross Profit | 7.19M | 9.26M | 4.44M | 3.61M |
| Operating Income | -30,576,782 | -35,408,007 | 2.40M | 1.91M |
| Net Income | -23,204,136 | -26,870,461 | 2.41M | 1.66M |
| Gross Margin | 89.4% | 89.4% | 49.8% | 49.8% |
| Operating Margin | -379.8% | -341.8% | 27.0% | 26.3% |
| Profit Margin | -288.3% | -273.9% | 27.1% | 22.9% |
| Rev Growth | -22.3% | -22.3% | +22.0% | +4.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 47.83M | 54.68M |
| Total Equity | — | — | 88.94M | 80.81M |
| D/E Ratio | — | — | 0.54 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -30,480,324 | -37,257,215 | 4.31M | 3.06M |
| Free Cash Flow | — | — | 1.46M | 1.28M |